A Study to Estimate Secukinumab Retention Rate in Psoriasis Patients With MASLD
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-100
SponsorNovartis Pharmaceuticals
About this trial
This study aims to examine the retention rate of secukinumab in adult patients with plaque psoriasis (with or without psoriatic arthritis \[PsA\]) and metabolic dysfunction-associated steatotic liver disease (MASLD) in routine clinical practice in Spain, as well as hepatic biomarker trajectories. The study will use electronic medical record (EMR) data from multiple Spanish hospitals.
Eligibility criteria
Qualifiers
Patients with a first recorded secukinumab prescription between 01 January 2021 and 31 December 2023.
Patients aged ≥18 years at index date.
Patients with no prior secukinumab exposure in available EMR history.
Secukinumab must be patient's first-, second-, or third-line biologic therapy for psoriasis/psoriatic arthritis (PsA).
Disqualifiers
Patients with evidence of MASLD absence.
Patients with malignant liver disease.
Patients with a history of liver transplantation.
Patients with alcohol use disorder.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
150 Participants
are grouped into 1 trial groupSponsors and collaborators
Source ClinicalTrials.gov